Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for Parkinson's Hallucinations
NCT04167813Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Oct 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ondansetron in Parkinson's disease (PD) and dementia with Lewy bodies (DLB) (2 arms), sponsored by University College London. Primary endpoint: Hallucinations at 12 weeks. Started Oct 2021; status: active, not recruiting.
02
Drugs
ondansetron
03
Conditions
Parkinson's disease (PD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT04167813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167813.